Researchers Create New Anti-cancer Drug Innovative Computer Modeling Techniques Utilized in Drug Development

HONOLULU- A team of University of Hawaii Cancer Center scientists have created a new type of anti-cancer drug, named BP-1-102 that targets a key protein that triggers the development of many types of cancer including lung, breast, and skin cancers. The development of BP-1-102 was guided by the research teams computer based molecular analysis of the cancer causing Stat 3 protein that causes cancer by promoting abnormal cell growth in otherwise healthy cells.

A unique feature of BP-1-102 is that it remains highly effective against cancer even when administered in oral form. Presently, most anti-cancer drugs require intravenous (IV) administration in a clinic or hospital setting which increases the financial, physical and emotional burdens on cancer patients. In its experimental form, BP-1-102 has shown promise in treating breast and lung cancers. The research article is published in the May 22nd edition of theĀ Proceedings of the National Academy of Sciences.

Read More at University of Hawaii Cancer Center

Connect With Us
Join other physicians who are receiving our updates.
We hate spam. Your email address will not be sold or shared with anyone else.